Granted Patent
B2
US 12,668,626 · App. 17/638,372 · Granted Jun 30, 2026
Anti-IL31 antibodies for veterinary use
Inventors:
Shyr Jiann Li (Millbrae, CA); Lam Nguyen (Union City, CA); Hangjun Zhan (Foster City, CA)
Assignee:
Elanco US Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are various embodiments relating to anti-IL31 antibodies having enhanced binding to canine IL31 and feline IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines and felines. Antibodies with enhanced binding to canine IL31 and feline IL31 are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind canine and feline IL31 are also provided.
Claims (27)
1 . An antibody that binds to canine IL31 or feline IL31, wherein the antibody comprises:
a) a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 15; and
b) a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 20, a CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 23 or SEQ ID NO: 24.
2 . The antibody of claim 1 , wherein the antibody comprises:
a) a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15; and
b) a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 20, a CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 24.
3 . The antibody of claim 1 comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7.
4 . The antibody of claim 1 comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.
5 . The antibody of claim 1 , wherein the antibody comprises:
a) a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15; and
b) a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 20, a CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 24;
wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence with at least 95% identity to SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence with at least 95% identity to SEQ ID NO: 10.
6 . The antibody of claim 5 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence with at least 98% identity to SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence with at least 98% identity to SEQ ID NO: 10.
7 . The antibody of claim 5 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence with at least 99% identity to SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence with at least 99% identity to SEQ ID NO: 10.
8 . The antibody of claim 5 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10.
9 . The antibody of claim 1 comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, or SEQ ID NO: 90.
10 . The antibody of claim 1 comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 52, SEQ ID NO: 53, or SEQ ID NO: 54.
11 . A bispecific antibody comprising the antibody of claim 1 and an antibody that binds to an antigen selected from IL17, TNFα, CD20, CD19, CD25, IL4, IL13, IL23, IgE, CD11α, IL6R, α4-Intergrin, IL12, IL1β, and BlyS.
12 . A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
13 . A method of treating a canine or feline having an IL31-induced condition, the method comprising administering to the canine or feline a therapeutically effective amount of the pharmaceutical composition of claim 12 , wherein the IL31-induced condition is selected from atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma, and eczema.
14 . A method of reducing IL31 signaling function in a cell expressing an IL31 receptor, the method comprising exposing to the cell the pharmaceutical composition of claim 12 in the presence of the IL31.
15 . A method of treating a canine or feline having an IL31-induced condition, the method comprising administering to the canine or feline a therapeutically effective amount of the antibody of claim 1 , wherein the IL31-induced condition is selected from atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma, and eczema.
16 . A method of reducing IL31 signaling function in a cell expressing an IL31 receptor, the method comprising exposing to the cell the antibody of claim 1 in the presence of the IL31.
17 . A method for detecting IL31 in a sample from a canine or feline comprising contacting the sample with the antibody of claim 1 under conditions permissive for binding of the antibody to IL31, and detecting a complex formed between the antibody and IL31 in the sample.
18 . An isolated nucleic acid encoding the antibody of claim 1 .
19 . A host cell comprising the nucleic acid of claim 18 .
20 . A method of producing the antibody encoded by the nucleic acid of claim 18 , comprising culturing a host cell transformed or transfected with the nucleic acid, and isolating the antibody.
Assignments (2)
MERGER AND CHANGE OF NAME
Recorded Oct 2, 2023
From: KINDRED BIOSCIENCES, INC.; ELANCO US INC.
To: ELANCO US INC.
Reel/Frame 065091/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 23, 2023
From: LI, SHYR JIANN; NGUYEN, LAM; ZHAN, HANGJUN
To: KINDRED BIOSCIENCES, INC.
Reel/Frame 062782/0387 →
Continuity (3)
Provisional Application
62894526
· Aug 30, 2019
Provisional Application
62893799
· Aug 29, 2019
References Cited (400)
US 5760185A
· Kimachi et al.
· 1998
[cited by applicant]
US 5795965A
· Tsuchiya et al.
· 1998
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 7514077B2
· Yao et al.
· 2009
[cited by applicant]
US 7531636B2
· Siadak et al.
· 2009
[cited by applicant]
US 7531637B2
· Siadak et al.
· 2009
[cited by applicant]
US 7615213B2
· Kasaian et al.
· 2009
[cited by applicant]
US 7638126B2
· Yao et al.
· 2009
[cited by applicant]
US 7939068B2
· Yao et al.
· 2011
[cited by applicant]
US 8017122B2
· Siadak et al.
· 2011
[cited by applicant]
US 8101183B2
· Siadak et al.
· 2012
[cited by applicant]
US 8105590B2
· Yao et al.
· 2012
[cited by applicant]
US 8133899B2
· Milton-Fry et al.
· 2012
[cited by applicant]
US 8377438B2
· Yao et al.
· 2013
[cited by applicant]
US 8388964B2
· Leung et al.
· 2013
[cited by applicant]
US 8460667B2
· Blanc et al.
· 2013
[cited by applicant]
US 8466262B2
· Siadak et al.
· 2013
[cited by applicant]
US 8470979B2
· Bondeensgaard et al.
· 2013
[cited by applicant]
US 8568723B2
· Siadak et al.
· 2013
[cited by applicant]
US 8637015B2
· Yao et al.
· 2014
[cited by applicant]
US 8790651B2
· Bammert et al.
· 2014
[cited by applicant]
US 8968732B2
· Yao et al.
· 2015
[cited by applicant]
US 9156909B2
· Siadak et al.
· 2015
[cited by applicant]
US 9206253B2
· Bammert et al.
· 2015
[cited by applicant]
US 9328164B2
· Gearing
· 2016
[cited by applicant]
US 9409986B2
· Wu et al.
· 2016
[cited by applicant]
US 9447183B2
· Wu et al.
· 2016
[cited by applicant]
US 9447184B2
· Wu et al.
· 2016
[cited by applicant]
US 9512219B2
· Siadak et al.
· 2016
[cited by applicant]
US 9556280B2
· Murphy et al.
· 2017
[cited by applicant]
US 9592293B2
· Wu et al.
· 2017
[cited by applicant]
US 9605062B2
· Sprecher et al.
· 2017
[cited by applicant]
US 9683037B2
· Siadak et al.
· 2017
[cited by applicant]
US 9822177B2
· Siadak et al.
· 2017
[cited by applicant]
US 20060182743A1
· Bilsborough
· 2006
[cited by applicant]
US 20060228329A1
· Brady et al.
· 2006
[cited by applicant]
US 20090110685A1
· Patel et al.
· 2009
[cited by applicant]
US 20090280121A1
· Leung et al.
· 2009
[cited by applicant]
US 20090300776A1
· Lecron et al.
· 2009
[cited by applicant]
US 20110123440A1
· Hansen et al.
· 2011
[cited by applicant]
US 20110165063A1
· Hsieh et al.
· 2011
[cited by applicant]
US 20110287454A1
· Wagner
· 2011
[cited by applicant]
US 20120100155A1
· Stoloff et al.
· 2012
[cited by applicant]
US 20120275996A1
· Hsieh
· 2012
[cited by applicant]
US 20130177563A1
· Leung et al.
· 2013
[cited by applicant]
US 20130216542A1
· Siadak et al.
· 2013
[cited by applicant]
US 20140286958A1
· Bammert et al.
· 2014
[cited by applicant]
US 20150004161A1
· Zhu et al.
· 2015
[cited by applicant]
US 20150037331A1
· Siadak et al.
· 2015
[cited by applicant]
US 20160024201A1
· Leung et al.
· 2016
[cited by applicant]
US 20160272703A1
· Hsieh et al.
· 2016
[cited by applicant]
US 20170058027A1
· Wu et al.
· 2017
[cited by applicant]
US 20170096484A1
· Leung et al.
· 2017
[cited by applicant]
US 20170158671A1
· Zhu et al.
· 2017
[cited by applicant]
US 20180066050A1
· Yao et al.
· 2018
[cited by applicant]
US 20180155418A1
· Sprecher et al.
· 2018
[cited by applicant]
US 20180215805A1
· Hjerrild et al.
· 2018
[cited by applicant]
US 20190040125A1
· Leung et al.
· 2019
[cited by applicant]
US 20190119372A1
· Yao et al.
· 2019
[cited by applicant]
US 20190169285A1
· Li et al.
· 2019
[cited by applicant]
US 20190330366A1
· Eckelman et al.
· 2019
[cited by applicant]
US 20190338020A1
· Sprecher et al.
· 2019
[cited by applicant]
US 20190389944A1
· Bammert et al.
· 2019
[cited by applicant]
US 20200048627A1
· Igawa et al.
· 2020
[cited by applicant]
US 20200069814A1
· Zhao et al.
· 2020
[cited by applicant]
US 20200181258A1
· Leger et al.
· 2020
[cited by applicant]
US 20210009678A1
· Hammerberg et al.
· 2021
[cited by applicant]
US 20210169896A1
· Zhao et al.
· 2021
[cited by applicant]
US 20210388053A1
· Zhan et al.
· 2021
[cited by applicant]
US 20210393790A1
· Zhao et al.
· 2021
[cited by applicant]
US 20220049002A1
· Li et al.
· 2022
[cited by applicant]
US 20220064263A1
· Zhan et al.
· 2022
[cited by applicant]
CN 105722992A
· 2016
[cited by applicant]
EP 1270595A1
· 2003
[cited by applicant]
EP 1500329A2
· 2005
[cited by applicant]
EP 1827485A2
· 2007
[cited by applicant]
EP 2215124A1
· 2010
[cited by applicant]
EP 2301965A1
· 2011
[cited by applicant]
EP 2493925A1
· 2012
[cited by applicant]
EP 2611462A2
· 2013
[cited by applicant]
EP 2703486A1
· 2014
[cited by applicant]
EP 2705053A1
· 2014
[cited by applicant]
EP 2710040A1
· 2014
[cited by applicant]
EP 2734549A1
· 2014
[cited by applicant]
EP 2734549B1
· 2014
[cited by applicant]
EP 2764026A2
· 2014
[cited by applicant]
EP 2842573A1
· 2015
[cited by applicant]
EP 2968454A1
· 2016
[cited by applicant]
EP 3219729A1
· 2017
[cited by applicant]
EP 3227342A1
· 2017
[cited by applicant]
EP 2829551B1
· 2017
[cited by applicant]
EP 2644698B1
· 2018
[cited by applicant]
JP 2014529295A
· 2014
[cited by applicant]
JP 6022563B2
· 2016
[cited by applicant]
RU 2444528A
· 2009
[cited by applicant]
RU 2009111884A
· 2010
[cited by applicant]
WO 2003060080A2
· 2003
[cited by applicant]
WO 2006081573A2
· 2006
[cited by applicant]
WO 2006088855A1
· 2006
[cited by applicant]
WO 2006088955A2
· 2006
[cited by applicant]
WO 2006122079A1
· 2006
[cited by applicant]
WO 2007143231A2
· 2007
[cited by applicant]
WO 2008028192A2
· 2008
[cited by applicant]
WO 2008086505A2
· 2008
[cited by applicant]
WO 2009071696A2
· 2009
[cited by applicant]
WO 2007133816A3
· 2010
[cited by applicant]
WO 2011047262A2
· 2011
[cited by applicant]
WO 2011065935A1
· 2011
[cited by applicant]
WO 2011106528A1
· 2011
[cited by applicant]
WO 2013011407A1
· 2013
[cited by applicant]
WO 2014191391A1
· 2014
[cited by applicant]
WO 2014208645A1
· 2014
[cited by applicant]
WO 2015042596A1
· 2015
[cited by applicant]
WO 2015067755A2
· 2015
[cited by applicant]
WO 2015086830A1
· 2015
[cited by applicant]
WO 2015151079A2
· 2015
[cited by applicant]
WO 2017025698A1
· 2017
[cited by applicant]
WO 2018073185A1
· 2018
[cited by applicant]
WO 2018156180A1
· 2018
[cited by applicant]
WO 2018156367A1
· 2018
[cited by applicant]
WO 2019118512A2
· 2019
[cited by applicant]
WO 2019177697A2
· 2019
[cited by applicant]
WO 2020073345A1
· 2020
[cited by applicant]
WO 2020155017A1
· 2020
[cited by applicant]
WO 2020257998A1
· 2020
[cited by applicant]
WO 2020258893A1
· 2020
[cited by applicant]
WO 2021041972A1
· 2021
[cited by applicant]
WO 2021115240A1
· 2021
[cited by applicant]
WO 2021123092A1
· 2021
[cited by applicant]
WO 2021123094A1
· 2021
[cited by applicant]
WO 2021165417A1
· 2021
[cited by applicant]
WO 2021188631A1
· 2021
[cited by applicant]
WO 2021212081A1
· 2021
[cited by applicant]
WO 2021212638A1
· 2021
[cited by applicant]
WO 2021216810A1
· 2021
[cited by applicant]
WO 2021216899A1
· 2021
[cited by applicant]
WO 2022029447A1
· 2022
[cited by applicant]
WO 2022049614A1
· 2022
[cited by applicant]
Tominaga et al., “In Vitro Model for Penetration of Sensory Nerve Fibers on a Matrigel Basement Membrane: Implication for Possible Application to Intractable Pruritus,” British Journal of Dermatology, 2009, 161:1028-103…
[cited by applicant]
UniProt Database, IL31 Ra,
[cited by applicant]
UniProt Database, Interleukin 31,
[cited by applicant]
UniProt Database, OSMR,
[cited by applicant]
Venereau et al., “Definition and Characterization of an Inhibitor for Interleukin-31,” Journal of Biological Chemistry, 2010, 285(20):14955-14963.
[cited by applicant]
Wai et al., “Interleukin-31 Induces Cytokine and Chemokine Production from Human Bronchial Epithelial Cells Through Activation of Mitogen-Activated Protein Kinase Signalling Pathways: Implications for the Allergic Respo…
[cited by applicant]
Winthrop, “The Emerging Safety Profile of JAK Inhibitors in Rheumatic Disease,” Nat Rev Rheumatol, 2017, 13(4):234-243, and correction (1 page).
[cited by applicant]
Wood et al., “Despite Identifying Some Shared Gene Associations with Human Atopic Dermatitis the use of Multiple Dog Breeds from Various Locations Limits Detection of Gene Associations in Canine Atopic Dermatitis,” Vet …
[cited by applicant]
Wood et al., “Gene Expression in Canine Atopic Dermatitis and Correlation with Clinical Severity Scores,” J Dermatol Sci, 2009, 55(1 ):27-33.
[cited by applicant]
Wood et al., “Reference Genes for Canine Skin When Using Quantitative Real-Time PCR,” Vet Immunol Immunopathol, 2008, 126(3-4):392-395.
[cited by applicant]
Xia et al., “Interleukin 31 and Atopic Dermatitis,” Intl Journal of Immunol, 2008, 31 (5):383-386.
[cited by applicant]
Yagi et al., “Interleukin-31 Stimulates Production of Inflammatory Mediators from Human Colonic Subepithelial Myofibroblasts.” Int J Mol Med, 2007, 19(6):941-946.
[cited by applicant]
Yasukawa et al., “Low-Dose Recombinant Canine Interferon-y for Treatment of Canine Atopic Dermatitis: An Open Randomized Comparative Trial of Two Doses,” Vet Dermatol, 2010, 21 (1):42-49.
[cited by applicant]
Zhang et al., “Structures and Biological Functions of IL-31 and IL-31 Receptors,” Cytokine Growth Factor Rev., 2008, 19(5-6):347-356, NIH public access version, 18 pages.
[cited by applicant]
“Amended Claims With Annotations”, filed Jul. 16, 2020 in Opposition of EP 2734549 (156 pages).
[cited by applicant]
Akira, Shizuo, “Functional Roles of STAT Family Proteins: Lessons from Knockout Mice,” Stem Cells, (1999), vol. 17:138-146.
[cited by applicant]
Anti-Feline IL-31 Functional Assay Data, filed in Opposition in EP 3219729 on Nov. 25, 2022 (1 page).
[cited by applicant]
Bachmann et al., “Vaccination against IL-31 for the treatment of atopic dermatitis in dogs,” Letters to the Editor, J Allergy Clin Immunol, (2018), vol. 142, No. 1: 279-281.e1, 4 pages.
[cited by applicant]
Bammert et al., “Genome-Wide Expression Patterns in
[cited by applicant]
Barber et al., “GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human issues,” Physiol Genomics, (2005), vol. 21: 389-395.
[cited by applicant]
Bergeron et al., “Comparative functional characterization of canine IgG subclasses,” Veterinary Immunology and Immunopathology, (2014), vol. 157, No. 1: 31-41.
[cited by applicant]
Butler et al., “Porcine IgG: structure, genetics, and evolution,” IMMUNOGENETICS, (2008), Springer, Berlin, DE, vol. 61, No. 3: 209-230.
[cited by applicant]
Canidae family information submitted in EP 2734549—12748547, dated Jul. 18, 2019, 2 pages.
[cited by applicant]
Carter, Paul J., “Potent antibody therapeutics by design,” Nature Reviews Immunology, (2006), Nature Pub. Group, GB, vol. 6: 343-357.
[cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol., 1994, 145 1):33-36.
[cited by applicant]
Data and sequence alignments submitted in EP 2734549-12748547, dated Jul. 18, 2019, 9 pages.
[cited by applicant]
Data submitted in EP 2734549-12748547, dated Jul. 18, 2019, 2 pages.
[cited by applicant]
De Bellis, Filippo, “Latest Thinking on Atopic Dermatitis in Cats and Dogs,” Apr. 7, 2014, Vet Times, 23 pages.
[cited by applicant]
Decision (Preliminary and Non-binding Opinion of the Opposition Division) and Summons to Attend Oral Proceedings, dated Feb. 28, 2022 in Opposition of EP 3219729 (18 pages).
[cited by applicant]
Decision of the Board of Appeal, EP Opposition EP12748547.2-EP 2734549, dated Apr. 1, 2022, 8 pages.
[cited by applicant]
Declaration of Assistant Prof. Adam Rudinsky, DVM, MS, DACVIM, submitted in Opposition to EP 2734549, dated Jul. 16, 2019, 12 pages.
[cited by applicant]
Declaration of Dr. Anthony Yu, BSc, DVM, MS, ADCD, submitted in Opposition to EP 2734549, dated Jul. 15, 2019, 20 pages.
[cited by applicant]
Declaration of Gary F. Bammert (Second), EP 2734549, EP 12748547, dated Jul. 14, 2020, 3 pages.
[cited by applicant]
Declaration of Gary F. Bammert, EP 2734549, EP 12748547, dated Aug. 28, 2019, 6 pages.
[cited by applicant]
Declaration of Prof. Dr. Ralf Mueller (First), EP 2734549—12748547, dated Jul. 21, 2018, 16 pages.
[cited by applicant]
Declaration of Prof. Dr. Ralf Mueller (Second), EP 2734549—12748547, dated Aug. 22, 2019, 6 pages.
[cited by applicant]
Declaration of Prof. Kun-Liang Guan, Ph.D., submitted in Opposition to EP 2734549, dated Jun. 23, 2019, 40 pages.
[cited by applicant]
Dreuw et al., “Characterization of the Signaling Capacities of the Novel gp130-like Cytokine Receptor*,” The Journal of Biological Chemistry, (2004), vol. 279, No. 34, Issue of Aug. 20: 36112-36120.
[cited by applicant]
Emboss Needle alignment canine IL31-mouse IL-31, submitted in Opposition in EP 3219729, (Nov. 2, 2021), 1 page.
[cited by applicant]
Emboss Needle alignment feline IL31-human IL-31, submitted in Opposition in EP 3219729, (Nov. 2, 2021), 1 page.
[cited by applicant]
Emboss Needle alignment feline IL31-mouse IL-31, submitted in Opposition in EP 3219729, (Nov. 2, 2021), 1 page.
[cited by applicant]
Emboss Needle alignment IL-31_felis catus (SEQ ID No. 70)_1L-31 canis lupus, Rundate: Oct. 31, 2021 (1 page).
[cited by applicant]
Emboss Needle alignment, submitted in Opposition in EP 3219729, (Nov. 2, 2021), 1 page.
[cited by applicant]
Experimental Report of IL-31-Induced Stat1-6 Phosphorylation, extracted from WO 2019177697, submitted in EP 2734549 Opposition, Mar. 11, 2011, 3 pages.
[cited by applicant]
Experimental Report of IL-31-Induced Stati-6 Phosphorylation, Filed in the European Patent Office Opposition to European Patent EP 2734549 B1, Jul. 18, 2019, 3 pages.
[cited by applicant]
Experimental report submitted in EP 2734549—12748547, dated Jul. 18, 2019, 3 pages.
[cited by applicant]
Favrot, C. “Feline allergic dermatitis: clinical aspects and diagnosis, ” (2013), ESVD-ECVD Annual Meeting, 5 pages.
[cited by applicant]
File History of U.S. Appl. No. 17/638,372, filed Feb. 25, 2022.
[cited by applicant]
Finkelstein et al., “Protein Physics,” Institute of Protein Research, (2016), Second, Updated and Extended Edition, Lecture 1, p. 11.
[cited by applicant]
Further Written Submissions of Opponent 01, filed Nov. 25, 2022 in Opposition of EP 3219729 (22 pages).
[cited by applicant]
Schulz et al., “A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema,” J Allergy Clin Immunol, (2007), vol. 120, No. 5: 1097-1102.
[cited by applicant]
Sequence Alignment performed Jul. 2, 2019, 3 pages.
[cited by applicant]
Stat3, Wikipedia, from Sep. 3, 2010, using the Internet archive service “Wayback Machine,” 1 page.
[cited by applicant]
Statement of grounds of appeal, EP Opposition EP12748547.2-EP 2734549, dated Feb. 28, 2020, 39 pages.
[cited by applicant]
Strohl, W. R., “Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters,” Biodrugs, (2015), vol. 29, No. 4: 215-239.
[cited by applicant]
Table of Antibodies—Excerpt from WO 2019-177697, cited in Opposition of EP 3219729 on Nov. 25, 2022 (1 page).
[cited by applicant]
Third Party Observations According to Art. 115 EPC, dated Apr. 14, 2015, filed in EP 2734549 (9 pages).
[cited by applicant]
Third Party Observations, EP Opposition EP 19196963.3-EP 3653645, dated Aug. 22, 2022, 12 pages.
[cited by applicant]
Tomasco et al., “Comparison of commercial DNA preparation kits for the detection of Brucellae in tissue using quantitative real-time PCR,” BMC Infectious Diseases, (2010), vol. 10: 100, 5 pages.
[cited by applicant]
Torres et al., “The immunoglobulin constant region contributes to affinity and specificity,” Trends in Immunology, (2008), vol. 29, No. 2: 91-97.
[cited by applicant]
Tricarico et al., “Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies,” Analytical Biochemistry, (2002),…
[cited by applicant]
UniProtKB—A0A3Q7TBT9 (A0A3Q7TBT9_VULVU), “Interleukin-31,” last modified Jun. 5, 2019, 3 pages.
[cited by applicant]
Vandesompele et al., “Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes,” Genome Biology, (2002), vol. 3(7): research0034.1-0034.11.
[cited by applicant]
Weber et al., “Assessment of mRNA and microRNA Stabilization in Peripheral Human Blood for Multicenter Studies and Biobanks,” Biomarker Insights, (2010), vol. 5: 95-102.
[cited by applicant]
Wisselink et al., “The efficacy of cyclosporine A in cats with presumed atopic dermatitis: A double blind, randomised prednisolone-controlled study,” The Veterinary Journal, (2009), vol. 180: 55-59.
[cited by applicant]
Yaseen et al., “Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in sclerodema,” Rheumatology, (2020), vol. 0: 1-12.
[cited by applicant]
Zoetis Press Release, Zoetis Receives European Commission Marketing Authorization for Cytopoint (lokivetmab), Apr. 26, 2017, 4 pages.
[cited by applicant]
Zoetis Press Release, “Zoetis Receives USDA License for CYTOPOINT,” Dec. 21, 2016, 4 pages.
[cited by applicant]
Aaronson et al., “A Road Map for Those Who Don't Know JAK-STAT,” Science, 2002, 296:1653-1655.
[cited by applicant]
Abdi, et al., “IL-31 Is an Inflammatory Pro-Fibrotic Factor Elevated in a Subset of Scleroderma Patients with Severe Pruritus,” Abstract No. 821, Arthritis Rheumatol, 2016 68(suppl 10), 2 pages.
[cited by applicant]
Advancing the Science of Atopic Dermatitis Treatment, Canine Atopic Dermatitis Immunotherapeutic Brochure, Zoetis, 2016, 8 pages.
[cited by applicant]
AlphaScreen kits brochure, Perkins Elmer, Mar. 2011, 2 pages.
[cited by applicant]
Bando et al., “Complete Overlap of Interleukin-31 Receptor A and Oncostatin M Receptor B in the Adult Dorsal Root Ganglia with Distinct Developmental Expression Patterns,” Neuroscience, 2006, 142(4): 1263-1271.
[cited by applicant]
Bieber et al., “Pathogenesis of Atopic Dermatitis: New Developments,” Allergic Dermatosis and Urticaria, (2009), vol. 9: 291-294.
[cited by applicant]
Bilsborough et al., “IL-31 is Associated with Cutaneous Lymphocyte Antigen-Positive Skin Homing T Cells in Patients with Atopic Dermatitis,” J Allergy and Clin Immunol, 2006, 117(2):418-425.
[cited by applicant]
Bilsborough et al., “IL-31 Receptor (IL-31 Ra) Knockout Mice Exhibit Elevated Responsiveness to Oncostatin M,” J Immunol, 2010, 185:6023-6030.
[cited by applicant]
Bogiatzi et al., “Cutting Edge: Proinflammatory and Th2 Cytokines Synergize to Induce Thymic Stromal Lymphopoietin Production by Human Skin Keratinocytes,” J Immunol, 2007, 178:3373-3377.
[cited by applicant]
Boguniewicz et al., “Atopic Dermatitis: A Disease of Altered Skin Barrier and Immune Dysregulation,” Immunol Rev., (2011), vol. 242, No. 1: 233-246.
[cited by applicant]
Brandt et al., Th2 Cytokines and Atopic Dermatitis, J Clin Cell Immunol., 2011, 2(3):110, 25 pages.
[cited by applicant]
Buddenkotte et al., “Pathophysiology and Therapy of Pruritus in Allergic and Atopic Diseases,” Allergy, 2010, 65:805-821.
[cited by applicant]
Canine Atopic Dermatitis Immunotherapeutic, First to Know Slides, 2015, found at http://o.zoetisus.com/rs/686-BYD-443/images/canine-il-31-first-to-know-slide-deck.pdf, 160 pages.
[cited by applicant]
Canine Atopic Dermatitis Immunotherapeutic: A Caninized Anti-cIL-31 Monoclonal Antibody, FAQ's, o.zoetisus.com/rs/686-BYD-443/images/canine-il-31-faqs.pdf, 16 pages.
[cited by applicant]
Carmi-Levy, et al., “A Modular View of Cytokine Networks in Atopic Dermatitis,” Clinic Rev Allerg Immunol, 2011, 41:245-253.
[cited by applicant]
Carr et al., “Investigation of the Pruitogenic Effects of Histamine, Serotonin, Tryptase, Substance P and Interleukin-2 in Healthy Dogs,” Vet Dermatol, 2009, 20(2): 105-110.
[cited by applicant]
Castellani et al., “IL-31 a TH2 Cytokine Involved in Immunity and Inflammation,” Int J Immunopathol Pharmacol, 2010, 23(3):709-713.
[cited by applicant]
Cevikbas et al., “Interleukin-31 Directly Regulates Neuronal Function in Inflammation and Itch,” Journal Inv. Derm. Abstract No. 700, 2010, 130:S117, 2 pages.
[cited by applicant]
Cevikbas et al., “A Sensory Neuron-Expressed IL-31 Receptor Mediates T helper Cell-Dependent Itch: Involvement of TRPV1 and TRPA1 ,” J Allergy Clin Immunol, 2014, 133:448-60, 460.e1-e7.
[cited by applicant]
Chattopadhyay et al., “Interleukin-31 and Oncostatin-M Mediate Distinct Signaling Reactions and Response Patterns in Lung Epithelial Cells,” Journal of Biological Chemistry, 2007, 282(5):3014-3026.
[cited by applicant]
Chen et al., “Restoration of Tight Junction Structure and Barrier Function by Down-Regulation of the Mitogen-Activated Protein Kinase Pathway in Ras-Transformed Madin-Darby Canine Kidney Cells,” Mol Biol Cell, 2000, 11 …
[cited by applicant]
Cheung et al., “Activation of Human Eosinophils and Epidermal Keratinocytes by Th2 Cytokine IL-31: Implication for the Immunopathogenesis of Atopic Dermatitis,” Int Immunol, 2010, 22(6):453-467.
[cited by applicant]
Cornelissen et al., “Signaling by IL-31 and Functional Consequences,” European Journal of Cell Biology, 2012, 91 :552-566.
[cited by applicant]
Cosgrove et al., “A Multicentre Clinical Trial to Evaluate the Efficacy and Field Safety of Oclacitinib,” Abstract FC-35, Veterinary Dermatology, 2012, 23(Suppl. 1), 1 page.
[cited by applicant]
Cytopoint, European Medicines Agency, European public assessment report (EPAR), 2017, 2 pages.
[cited by applicant]
Cytopoint™ ALK Technical Memo, Apr. 2017, Medical Scientific Affairs, 2 pages.
[cited by applicant]
Dambacher et al., “Interleukin 31 Mediates MAP Kinase and STAT1/3 Activation in Intestinal Epithelial Cells and its Expression is Upregulated in Inflammatory Bowel Disease,” Gut, 2007, 56:1257-1265.
[cited by applicant]
Darnell et al., “Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins,” Science, 1994, 264(5164):1415-1421, 7 pages.
[cited by applicant]
Dillon et al., “Interleukin 31, a Cytokine Produced by Activated T Cells, Induces Dermatitis in Mice,” Nature Immunology, 2004, 5(7):752-760.
[cited by applicant]
Diveu et al., “Predominant Expression of the Long Isoform of GP130-like (GPL) Receptor is Required for Interleukin-31 Signaling,” Eur. Cytokine Netw., 2004, 15(4): 291-302.
[cited by applicant]
Estep et al., “High Throughput Solution-Based Measurement of Antibody-Antigen Affinity and Epitope Binning,” mAbs, 2013, 5(2):270-278.
[cited by applicant]
Extended European Search Report for European Patent Application No. 18756690.6 dated Nov. 2, 2020, 9 pages.
[cited by applicant]
Ezzat et al., “Serum Measurement of Interleukin-31 (IL-31) in Paediatric Atopic Dermatitis: Elevated Levels Correlate with Severity Scoring,” JEADV, 2011, 25:334-339.
[cited by applicant]
Felsburg, “Overview of Immune System Development in the Dog: Comparison with Humans,” Hum Exp Toxicol, 2002, 21(9-10):487-92.
[cited by applicant]
File History of U.S. Appl. No. 15/467,464, filed Mar. 23, 2017.
[cited by applicant]
File History of U.S. Appl. No. 15/844,142, filed Dec. 15, 2017.
[cited by applicant]
File History of U.S. Appl. No. 16/186,013, filed Nov. 9, 2018.
[cited by applicant]
File History of U.S. Appl. No. 16/488,045, filed Aug. 22, 2019.
[cited by applicant]
Fleck, et al., “Comparison of the Janus Kinase (JAK) Inhibitor, Oclacitinib, and Prednisolone in Canine Models of Pruritus,” Abstract FC-36, Veterinary Dermatology, 2012, 23(Suppl. 1), 1 page.
[cited by applicant]
Gonzales et al., “Interleukin-31: Its Role in Canine Pruritus and Naturally Occurring Canine Atopic Dermatitis,” Vet Dermatol, 2013, 24:48-53 and e11-e12.
[cited by applicant]
Gonzales et al., “Oclacitinib (Apoquel®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy,” Journal of Veterinary Pharmacology and Therapeutics, 2014, 37:317-24.
[cited by applicant]
Gonzales et al., “Oclacitinib (Apoquel®; Zoetis) is a novel Janus kinase inhibitor that has activity against canine pro-allergic and pro-inflammatory cytokines,” Abstracts of the 25th Annual Congress of the ECVD-ESVD, S…
[cited by applicant]
Gonzolas, et al., “IL-31: Its Role in Canine Pruritus and Prevalence in Naturally Occurring Canine Atopic Dermatitis,” Abstract Supporting Original Study 5, Veterinary Dermatology, 2012, 23(Suppl. 1):6.
[cited by applicant]
Grimstad et al., “Anti-Interleukin-31-Antibodies Ameliorate Scratching Behaviour in NC/Nga Mice: A Model of Atopic Dermatitis,” Experimental Dermatology, 2009, 18(1):35-43.
[cited by applicant]
Gutzmer et al., “Pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus,” Frontiers in Bioscience S3, (2011), pp. 985-994.
[cited by applicant]
Gutzwiller, M. E. R., “Canine Dendritic Cells and Their Involvement in Atopic Dermatitis,” Dissertation, Bern, (2010), 69 pages.
[cited by applicant]
Haitina et al., The G Protein-Coupled Receptor Subset of the Dog Genome is More Similar to that in Humans than Rodents, BMC Genomics, 2009, 10:24, 13 pages.
[cited by applicant]
Halliwell et al., “The ACVD task force on canine atopic dermatitis (111): the role of antibodies in canine atopic dermatitis,” Veterinary Immunology and Immunpathology, 2001, 81 (3-4):159-167.
[cited by applicant]
Hashimoto et al., “Itch-Associated Scratching Contributes to the Development of Dermatitis and Hyperimmunoglobulinaemia E in NC/Nga Mice,” Experimental Dermatology, 2011, 20:820-825.
[cited by applicant]
Hashizume et al., “IL-6 Plays an Essential Role in Neutrophilia Under Inflammation,” Cytokine, 2011, 54:92-99.
[cited by applicant]
Grau-Vorster, et al., “Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow-derived multipotent mesenchymal stromal cell expansion cultures,” Cytotherapy. Jan. 2019;21(1):32-40…
[cited by applicant]
Chunxiu, et al., “Research progress on the correlation between interleukin-31 and atopic dermatitis,” China Medical Innovation. 2016 Issue 36 133-136 (Abstract Provided).
[cited by applicant]
Moyaert et al., “A Blinded, Randomized Clinical Trial Evaluating the Efficacy and Safety of Lokivetmab Compared to Ciclosporin in Client-Owned Dogs with Atopic Dermatitis,” Vet Dermatol, 2017, 28(6):593-603 and e144-e14…
[cited by applicant]
Nakamura et al., “Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors,” British J of Dermatol, 2003, 149:718-730.
[cited by applicant]
National Human Genome Research Institute (NHGRI), “Researchers Publish Dog Genome Sequence,” 2005, 2 pages.
[cited by applicant]
Nattkemper et al., “Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin,” Acta Derm Venereal, 2016, 96:894-898.
[cited by applicant]
Neis et al., “Enhanced Expression Levels of IL-31 Correlate with IL-4 and IL-13 in Atopic and Allergic Contact Dermatitis,” J Allergy Clin Immunol, 2006, 118(4):930-937.
[cited by applicant]
Niyonsaba et al., “Antimicrobial Peptides Human 13-Defensins and Cathelicidin LL-37 Induce the Secretion of a Pruritogenic Cytokine IL-31 by Human Mast Cells,” J Immunol, 2010, 184:3526-3534.
[cited by applicant]
Nobbe et al., “IL-31 Expression by Inflammatory Cells is Preferentially Elevated in Atopic Dermatitis,” Acta Derm Venereal, 2012, 92:24-28, comment on same at 92:5-6.
[cited by applicant]
Nuttall et al., “Expression of Th1, Th2 and Immunosuppressive Cytokine Gene Transcripts in Canine Atopic Dermatitis,” Clin Exp Allergy, 2002, 32(5):789-795.
[cited by applicant]
Nuttall et al., “T-Helper 1, T-helper 2 and Immunosuppressive Cytokines in Canine Atopic Dermatitis,” Veterinary Immunol Immunopathol, 2002, 87(3-4):379-384.
[cited by applicant]
O'Kennedy et al., “A Review of Enzyme-Immunoassay and a Description of a Competitive Enzyme-Linked Immunosorbent Assay for the Detection of Immunoglobulin Concentrations,” Biochemical Education, 1990, 18(3):136-140.
[cited by applicant]
Olivry et al., “Interventions for Atopic Dermatitis in Dogs: A Systematic Review of Randomized Controlled Trials,” Vet Dermatol, 2010, 21 :4-22.
[cited by applicant]
Olivry et al., “The ACVD Task Force on Canine Atopic Dermatitis: Forewords and Lexicon,” Veterinary Immunology and Immunpathology, 2001, 81 (3-4):143-146.
[cited by applicant]
Olivry et al., “Toward a Canine Model of Atopic Dermatitis Amplification of Cytokine-Gene Transcripts in the Skin of Atopic Dogs,” Exp Dermatol, 1999, 8(3):204-211.
[cited by applicant]
Olivry et al., “Treatment of Canine Atopic Dermatitis: 2010 Clinical Practice Guidelines from the International Task Force on Canine Atopic Dermatitis,” Vet Dermatol, 2010, 21 (3):233-248.
[cited by applicant]
O'Shea et al., “A New Modality for Immunosuppression: Targeting the JAK/STAT Pathway,” Nat Rev Drug Discov, 2004, 3(7):555-564.
[cited by applicant]
Pedersen et al., “Identification of Monoclonal Antibodies that Cross-React with Cytokines from Different Animal Species,” Vet Immunol and Immunopath, 2002, 88:111-122.
[cited by applicant]
Perrigoue et al., “IL-31-IL-31 R Interactions Limit the Magnitude of Th2 Cytokine-Dependent Immunity and Inflammation Following Intestinal Helminth Infection,” J Immunol, 2009, 182(10):6088-6094.
[cited by applicant]
Picco et al., “A Prospective Study on Canine Atopic Dermatitis and Food-Induced Allergic Dermatitis in Switzerland,” Vet. Dermatol, 2008, 19(3): 150-155.
[cited by applicant]
Post-published data from Zoetis for two anti-feline IL-31 antibodies (extracted from WO 2019/177697), submitted in Opposition in EP 3219729, (submitted on Mar. 11, 2011), 4 pages.
[cited by applicant]
Prelaud et al., “Reevaluation of Diagnostic Criteria of Canine Atopic Dermatitis,” Revue de Medecine Veterinaire, 1998, 149:1057-1064, English abstract only.
[cited by applicant]
Product Sheet, DH82, CRL-10389(TM), ATCC, 2021, 7 pages.
[cited by applicant]
Prost, C., “Feline atopic dermatitis: Clinical signs and diagnosis,” EJCAP, (2009), vol. 19, No. 3: 223-229.
[cited by applicant]
Pucheu-Haston et al., “A Canine Model of Cutaneous Late-Phase Reactions: Prednisolone Inhibition of Cellular and Cytokine Responses,” Immunology, 2005, 117:177-187.
[cited by applicant]
Raap et al., “Correlation of IL-31 Serum Levels with Severity of Atopic Dermatitis,” J Allergy Clin Immunol, 2008, 122(2):421-423.
[cited by applicant]
Raap et al., “Increased Levels of Serum IL-31 in Chronic Spontaneous Urticaria,” Exp. Dermatol., 2010, 19(5):464-466.
[cited by applicant]
Rawlings et al., The JAK/STAT Signaling Pathway, J Cell Science, 2004, 117:1281-1283.
[cited by applicant]
Reichmann et al., “Reshaping Human Antibodies for Therapy,” Nature, 1988, 332:323-327.
[cited by applicant]
Reply to appeal, EP Opposition EP12748547.2-EP 2734549, dated Jul. 16, 2020, 58 pages.
[cited by applicant]
Rudikoff et al. Proc. Natl. Acad. Sci. USA vol. 79, pp. 1979-1983 (Mar. 1982).
[cited by applicant]
Saeki et al., Thymus and Activation Regulated Chemokine (TARC)/CCL 17 and Skin Diseases, J Derma Science, 2006, 43:75-84.
[cited by applicant]
Saleem, et al., “Interleukin-31 Pathway and Its Role in Atopic Dermatitis: A Systematic Review,” J Dermatolg Treat., 2017, 28(7):591-599.
[cited by applicant]
Sandilands et al., “Filaggrin in the Frontline: Role in Skin Barrier Function and Disease,” J Cell Science, 2009, 122:1285-1294.
[cited by applicant]
Santoro, et al., “Canine and Human Atopic Dermatitis: Two Faces of the Same Host-Microbe Interaction,” J Investigative Dermatol, 2016, 136:1087-1089.
[cited by applicant]
Scheerlinck et al., “Functional and Structural Comparison of Cytokines in Different Species, ” Vet Immunol mmunopathol, 1999, 72(1-2):39-44.
[cited by applicant]
Schlothauer et al., “Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions,” Protein Engineering, Design and Selection, (2016), vol. 29, No. 10: 457-466.
[cited by applicant]
Schlotter et al., “Lesional Skin in Atopic Dogs Shows a Mixed Type-1 and Type-2 Immune Responsiveness,” Vet Immunol Immunopathol, 2011, 143(1-2):20-26.
[cited by applicant]
Schwartzman et al., “Canine Reaginic Antibody: Characterization of the Spontaneous Anti-Ragweed and Induced Anti-Dinitrophenyl Reaginic Antibodies of the Atopic Dog,” Clin. exp. Immunol., (1971), vol. 9: 549-569.
[cited by applicant]
Scott et al., “Treatment of Canine Atopic Dermatitis with a Commercial Homeopathic Remedy: A Single-Blinded, Placebo-Controlled Study,” Can Vet J, 2002, 43(8):601-603.
[cited by applicant]
Shen et al., “Single Variable Domain-IgG Fusion: A Novel Recombinant Approach to Fc Domain-Containing Bispecific Antibodies,” The Journal of Biological Chemistry, (2006), vol. 281, No. 16: 10706-10714.
[cited by applicant]
Song et al., “JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer and IL-6 Neutralizing Antibodies Can Suppress JAK1-STA T3 Signaling,” Mol Cancer Ther, 2011, 10(3):481-494.
[cited by applicant]
Sonkoly et al., “IL-31: A New Link Between T Cells and Pruritus in Atopic Skin Inflammation,” J Allergy Clin Immunol, 2006, 117(2):411-417.
[cited by applicant]
Soumelis et al., “Human Epithelial Cells Trigger Dendritic Cell-Mediated Allergic Inflammation by Producing TSLP,” Nat Immunol, 2002, 3(7):673-680.
[cited by applicant]
Sousa et al., “The ACVD Task Force on Canine Atopic Dermatitis (II): Genetic Factors,” Veterinary Immunology and Immunopathology, 2001, 81 (3-4):153-157.
[cited by applicant]
Strachan et al., “Family Size, Infection, and Atopy: The First Decade of the Hygiene Hypothesis,” Thorax, 2000, 55 (Suppl 1): S2-S10.
[cited by applicant]
Strietzel et al., “In Vitro functional characterization of feline IgGs,” Veterinary Immunology and Immunopathology, (2014), vol. 158, No. 3: 214-223.
[cited by applicant]
Suter et al., “The keratinocyte in epidermal renewal and defence,” Veterinary Dermatology, (2009), vol. 20, 515-532.
[cited by applicant]
Takaoka et al., “Expression of IL-31 Gene Transcripts in NC/Nga Mice with Atopic Dermatitis,” European Journal of Pharmacology, 2005, 516(2):180-181.
[cited by applicant]
Takaoka et al., “Involvement of IL-31 on Scratching Behavior in NC/Nga Mice with Atopic-Like Dermatitis,” Experimental Dermatology, 2006, 15(3):161-167.
[cited by applicant]
Tang, “Molecular Cloning of Canine IL-13 Receptor a Chain (a1 and a2) cDNAs and Detection of Corresponding mRNAs in Canine Tissues, ” Veterinary Immunology and Immunopathology, 2001, 79(3-4):181-195.
[cited by applicant]
Terada et al., “Clinical Comparison of Human and Canine Atopic Dermatitis Using Human Diagnostic Criteria: Proposal of Provisional Diagnostic Criteria for Canine Atopic Dermatitis,” Journal of Dermatology, 2011, 38:784-…
[cited by applicant]
Hashizume et al., The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis, Arthritis, 2011, Article ID 765624, 8 pages.
[cited by applicant]
Mizuno et al., “Molecular Cloning of Canine Interleukin-31 and its Expression in Various Tissues,” Veterinary Immunology and Immunopathology, 2009, 131 :140-143.
[cited by applicant]
Hawro et al., “Interleukin-31 Does Not Induce Immediate Itch in Atopic Dermatitis Patients and Healthy Controls after Skin Challenge,” Allergy, 2014, 69:113-117.
[cited by applicant]
Hill et al., “Pilot Study of the Effect of Individualised Homeopathy on the Pruritus Associated with Atopic Dermatitis in Dogs,” Vet. Rec., 2009, 164(12):364-70.
[cited by applicant]
Hill, R. E., “Center for Veterinary Biologics Notice No. 13-05,” United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Center for Veterinary Biologics, Ames, Iowa, dat…
[cited by applicant]
Hillier et al., The ACVD Task Force on Canine Atopic Dermatitis (I): Incidence and Prevalence, Veterinary Immunology and Immunopathology, 2001, 81 :147-151.
[cited by applicant]
Hirano et al., “Signaling Mechanisms Through gp130: A Model of the Cytokine System,” Cytokme & Growth Factor Reviews, (1997), vol. 8., No. 4: 241-252.
[cited by applicant]
Holsapple et al., “Species Comparison of Anatomical and Functional Immune System Development,” Birth Defects Res B Dev Reprod Toxicol., 2003, 68(4):321-34.
[cited by applicant]
Hong et al., “Functional Regulation of Interleukin-31 Production by its Genetic Polymorphism in Patients with Extrinsic Atopic Dermatitis,” Acta Derm Venereal, 2012, 92(4): 430-432.
[cited by applicant]
Humphrey, et al., “Development of a Model of IL-31 Induced Pruritus in Beagle Dogs,” Abstract FC-30, Veterinary Dermatology, 2012, 23(Suppl. 1), 1 page.
[cited by applicant]
Hvid et al., “IL-25 in Atopic Dermatitis: A Possible Link Between Inflammation and Skin Barrier Dysfunction,” J Invest Dermatol, 2011, 131 (1): 150-157.
[cited by applicant]
IL-31 Antibody (Aviva Systems Biology) Oct. 11, 2016 [retrieved on Apr. 24, 2018, www.avivasysbio.com/en/il31-antibody-n-terminal-region-oaab05980.html], 2 pages.
[cited by applicant]
IL-31 Antibody: (Aviva Systems Biology) Publication date [retrieved on Apr. 24, 2018, www.google.com/search?q=I L31 +Antibody+-+N-terminal+reg ion+%280AAB05980%29+from+Aviva+Systems+Biology&rlz=1 C1 Ggrv _ en U S769US76…
[cited by applicant]
IL-31 sequence alignments, submitted in Opposition in EP 3219729, (submitted on Jun. 9, 2021), 1 page.
[cited by applicant]
ImmunoGlobe® product information, Antikorpertechnik GmbH, 2 pages.
[cited by applicant]
Incorvaia et al., “Allergy and the skin,” Clinical and Experimental Immunology, (2008), vol. 153, Suppl. 1: 27-29.
[cited by applicant]
International Nonproprietary Names for Pharmaceutical Substances (INN) excerpt for Lokivetmab, WHO Drug Information, 2015, 29(3):407-408.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2018/017623, dated May 15, 2018, 15 pages.
[cited by applicant]
International Search Report received in PCT/US2017/023788, dated Jun. 6, 2017, 12 pages.
[cited by applicant]
Janeway et al. Immunology, 3rd ed., 1997, Garland Publications, Inc., pp. 3:1-3: 11.
[cited by applicant]
Javens et al., “Oclacitinib Inhibits Canine IL-4 and IL-13-activated JAK-STAT Pathways in Canine DH82 Cells,” 2018 3pt Proceedings of the North American Veterinary Dermatology Forum, May 1-5, 2018, p. 104.
[cited by applicant]
Jin et al., “Animal Models of Atopic Dermatitis,” J Invest Dermatol, 2009, 129(1):31-40.
[cited by applicant]
Michels et al., “A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis,” Vet Der…
[cited by applicant]
Kanda et al., “Characterization of Canine Filaggrin: Gene Structure and Protein Expression in Dog Skin,” Vet Dermatol, 2013, 24:25-31, e7.
[cited by applicant]
Kasraie et al., “Interleukin (IL)-31 Induces Pro-Inflammatory Cytokines in Human Monocytes and Macrophages Following Stimulation with Staphylococcal Exotoxins,” Allergy, 2010, 65:712-721.
[cited by applicant]
Kasraie et al., “Functional Effects of Interleukin 31 in Human Primary Keratinocytes,” Allergy, 2011, 66:845-852.
[cited by applicant]